2.50
Hdl Handle:
http://hdl.handle.net/10541/67991
Title:
Acromegaly, growth hormone and cancer risk.
Authors:
Renehan, Andrew G; Brennan, Bernadette M
Abstract:
Acromegaly is an endocrine disorder characterized by sustained hypersecretion of growth hormone (GH) with concomitant elevation of insulin-like growth factor I (IGF-I) associated with premature mortality from cardiopulmonary diseases and certain malignancies. In particular, there is a two-fold increased risk of developing colorectal cancer. Possible mechanisms underlying this association include elevated levels of circulating GH and IGF-I, but several other plausible processes may be relevant. In a parallel literature, there has been debate whether GH replacement therapy is associated with increased cancer risk in three scenarios: (1) tumour recurrence in children with previously treated cancer; (2) second neoplasms (SNs) in survivors of childhood cancer treated with GH; and (3) de-novo cancer in non-cancer patients treated with GH. The general evidence suggests no increased risk in scenario 1. Through a maze of complex study designs, there is inconclusive evidence of a very modest increase in cancer risk in treated GH-deficiency patients in scenarios 2 and 3, but it is likely that the cumulative risk equates to that of the general population. This emphasizes the need for patient selection balanced against the known morbidity of untreated GH deficiency.
Affiliation:
School of Cancer and Imaging Sciences, University of Manchester, Manchester, UK. arenehan@picr.man.ac.uk
Citation:
Acromegaly, growth hormone and cancer risk. 2008, 22 (4):639-57 Best Pract. Res. Clin. Endocrinol. Metab.
Journal:
Best Practice & Research. Clinical Endocrinology & Metabolism
Issue Date:
Aug-2008
URI:
http://hdl.handle.net/10541/67991
DOI:
10.1016/j.beem.2008.08.011
PubMed ID:
18971124
Type:
Article
Language:
en
ISSN:
1532-1908
Appears in Collections:
All Christie Publications ; School of Cancer and Imaging Sciences; Surgery

Full metadata record

DC FieldValue Language
dc.contributor.authorRenehan, Andrew G-
dc.contributor.authorBrennan, Bernadette M-
dc.date.accessioned2009-05-12T18:21:31Z-
dc.date.available2009-05-12T18:21:31Z-
dc.date.issued2008-08-
dc.identifier.citationAcromegaly, growth hormone and cancer risk. 2008, 22 (4):639-57 Best Pract. Res. Clin. Endocrinol. Metab.en
dc.identifier.issn1532-1908-
dc.identifier.pmid18971124-
dc.identifier.doi10.1016/j.beem.2008.08.011-
dc.identifier.urihttp://hdl.handle.net/10541/67991-
dc.description.abstractAcromegaly is an endocrine disorder characterized by sustained hypersecretion of growth hormone (GH) with concomitant elevation of insulin-like growth factor I (IGF-I) associated with premature mortality from cardiopulmonary diseases and certain malignancies. In particular, there is a two-fold increased risk of developing colorectal cancer. Possible mechanisms underlying this association include elevated levels of circulating GH and IGF-I, but several other plausible processes may be relevant. In a parallel literature, there has been debate whether GH replacement therapy is associated with increased cancer risk in three scenarios: (1) tumour recurrence in children with previously treated cancer; (2) second neoplasms (SNs) in survivors of childhood cancer treated with GH; and (3) de-novo cancer in non-cancer patients treated with GH. The general evidence suggests no increased risk in scenario 1. Through a maze of complex study designs, there is inconclusive evidence of a very modest increase in cancer risk in treated GH-deficiency patients in scenarios 2 and 3, but it is likely that the cumulative risk equates to that of the general population. This emphasizes the need for patient selection balanced against the known morbidity of untreated GH deficiency.en
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subjectThyroid Canceren
dc.subject.meshAcromegaly-
dc.subject.meshChild-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshHormone Replacement Therapy-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshInsulin-Like Growth Factor I-
dc.subject.meshThyroid Neoplasms-
dc.titleAcromegaly, growth hormone and cancer risk.en
dc.typeArticleen
dc.contributor.departmentSchool of Cancer and Imaging Sciences, University of Manchester, Manchester, UK. arenehan@picr.man.ac.uken
dc.identifier.journalBest Practice & Research. Clinical Endocrinology & Metabolismen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.